glp-1/gip receptor agonists The Effects of Dual Agonism on Glucagon Secretion—A Review Targeting GLP-1, GIP & GCG

IH has received grants from AstraZeneca/Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lexicon Pharmaceuticals, Medtronic, Merck & Co., Novo Nordisk, the Population Health Research Institute and Sanofi

The STEP-HFpEF trial randomised 529 patients with obesity (BMI 30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] 45%) and New York Heart Association (NYHA) Class II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo

Lancet 377:13411352 Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW (2012) Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP)

Lithium chloride-induced anorexia, but not conditioned taste aversions, in rats with area postrema lesions

In March 2026, a Foundayo is notable not only for its oral formulation but also for being among the first medications approved under the FDAs new Additionally, unlike other oral GLP-1s, it does not require the fasting and water restrictions associated with oral semaglutide, potentially making it more accessible